Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus best supportive care vs best supportive care in chemotherapy-refractory KRAS wild-type metastatic colorectal cancer
CTR20160256Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in colorectal adenocarcinoma, colon adenocarcinoma, rectal adenocarcinoma, sponsored by Amgen. Started Aug 2016; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal adenocarcinomacolon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on CTR20160256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160256.